According to GlobalData, INTERSTIM is one of 128 product lines sold in the US neuromodulation devices market; these product lines are sold by 17 different manufacturers. The average selling price for ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
Medtronic plc. MDT has submitted its rechargeable, implantable sacral neuromodulation (SNM) device known as InterStim Micro neurostimulator for the FDA’s pre-market approval (PMA). This PMA supplement ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life improvements for ...
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...
Medtronic plc. MDT has submitted its rechargeable, implantable sacral neuromodulation (SNM) device known as InterStim Micro neurostimulator for the FDA’s pre-market approval (PMA). This PMA supplement ...
(WNDU) - It’s a taboo topic that nobody talks about. But 1 in 6 Americans suffer with either urinary or bowel incontinence. That’s more than the number of people with Alzheimer’s, diabetes, or breast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback